newsfilter
← Earnings
Earnings Releases·

Nuo Therapeutics — Third Quarter 2026 Earnings Summary

  • Q3 2026 total revenues reached $1.9 million, an 80% year-over-year increase, while nine-month revenues rose 123% to $4.9 million; Q3 product revenues grew 5% sequentially, driven by a 17% sequential increase in Aurix wound care sales.
  • Net operating loss improved by $166,000 year-over-year to $374,000 but increased $208,000 sequentially due to higher stock-based compensation, credit loss provisions, and over $100,000 in regulatory costs related to component supply.
  • Cash reserves declined to $80,941 as of September 30, 2026, from $548,946 at year-end 2025, while total borrowings under the loan agreement reached $2,000,000 following a $325,000 subsequent funding tranche.
  • Future outlook includes a 7% increase in Medicare OPPS reimbursement for G0465 to $2,257 in 2027 and expanded coverage for nursing home treatments effective January 1, 2027, supporting a strategic focus on hospital segment growth and operational breakeven.
  • Aurix achieved its highest hospital setting quarter ever, with HOPD sales as a percentage of total wound care sales more than doubling since Q1 2026, alongside a $250,000 reimbursement milestone received from Smith+Nephew.
Company
NUO THERAPEUTICS INC
Sector
Healthcare
Industry
Medical Devices